NewsSource: EClinCloud

Ahead of the Launch Event: A Brief Look at Putting "Patient-Centricity" into Practice in Clinical Trials

3 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.



The core purpose of new drug R&D is to address patients' needs. Patients' actual experiences and real needs bring unique and valuable perspectives to drug development. These perspectives help improve the quality, relevance, safety, and efficiency of drug development and inform regulatory decision-making.



How to Achieve "Patient-Centricity"

"Patient-centricity" may seem like a simple phrase, yet it is easier said than done. Undeniably, many challenges remain in collecting and applying real-world evidence, involving issues such as patient privacy, data formatting, and data security; from data capture to data quality and standardization, everything is still in an exploratory stage.


In recent years, however, patient-centric clinical trials for drug development have been shifting toward digitalization, adopting methodologically sounder tools to identify, collect, and analyze patient data so as to obtain clinical outcomes as objectively and comprehensively as possible in clinical research. In addition, policies introduced to better protect patients' medication rights and interests—such as the "4+7" volume-based procurement, consistency evaluation, and DRG-based medical insurance cost control—have placed higher demands on the R&D efficiency of innovative drug developers, further compelling pharmaceutical companies to pursue digital transformation in clinical research.


On the premise of safeguarding patient safety and ensuring data quality and study continuity, reducing subject burden in a safe, convenient, and rapid manner is an essential path for pharmaceutical companies and sponsors to achieve "patient-centricity."



How Do Pharmaceutical Companies Interpret "Patient-Centricity"?

One well-known pharmaceutical company defines it as: "Practicing 'patients first' through open and ongoing communication, and acting with sincerity and care to achieve the best treatment outcomes and experiences for patients and their families."


Another well-known pharmaceutical company has established a decision-making framework in which patient-centric options are given priority. The company's national sales head noted that this framework can be summarized in four words—patients, trust, reputation, and business—and that whenever an important decision has to be made or a strategic option chosen, patients are considered first.



EClinCloud's Products Will Assist Sponsors in

Continuously Deepening "Patient-Centricity" in Clinical Trials

In June 2020, the U.S. FDA issued the guidance for industry "Patient-Focused Drug Development: Collecting Comprehensive and Representative Input," aimed at guiding investigators, product developers, and other stakeholders on how to collect and submit comprehensive and representative patient input for medical product development and regulatory decision-making.


Guided by technological innovation and precision medicine evaluation standards, EClinCloud's "patient-centric" and "data-driven" integrated clinical evidence support SaaS platform can genuinely improve pharmaceutical companies' clinical research efficiency.



EClinCloud Product Launch Event

On July 17, EClinCloud will hold its "Digital Breakthrough: Ascending Together with EClinCloud" integrated clinical trial cloud platform launch event. EClinCloud CEO Qin Long will deliver a keynote speech at the event to explain how the integrated cloud platform puts patients at the center and addresses pain points in clinical trials. (Registration details are noted at the bottom of the image below; EClinCloud looks forward to your attendance.)

Event Date: July 17, 2022

Event Venue: Shangri-La Qiantan, Shanghai



Article illustration





About EClinCloud



EClinCloud is a healthcare and life-sciences technology company rooted in China and serving the world. Guided by its mission of "Bringing Effective Treatments to Patients Through Technological Innovation" and driven by science and medicine, it combines digital technology with life-sciences data to build an end-to-end digital clinical trial cloud platform and provide technical solutions for clinical endpoint assessment, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article illustration


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.